The mechanisms underlying hypercalciuria in pseudohypoaldosteronism type II (PHAII) 
The mechanisms underlying hypercalciuria in pseudohypoaldosteronism type II (PHAII) caused by WNK4 mutations remain unclear. In this study, we used Wnk4 D561A/ϩ knock-in mice as a model of human PHAII for investigating the pathogenesis of hypercalciuria in PHAII. P seudohypoaldosteronism type II (PHAII) is an autosomal dominant disorder characterized by salt-sensitive hypertension, hyperkalemia, and metabolic acidosis (1) . Patients with PHAII are usually sensitive to thiazide treatment, suggesting gain-of-function in the thiazide-sensitive NaCl cotransporter (NCC) in the distal convoluted tubule as a major pathogenic mechanism (2) . Despite no mutations identified in the SLC12A3 gene encoding the NCC, mutations in genes encoding two upstream regulatory kinases, with-no-lysine [K] kinase (WNK) 1 and 4, have been found in patients with PHAII. Mutations in the WNK1 gene are large deletions of the first intron resulting in increased expression of the gene. Mutations in the WNK4 gene are missense mutations outside the protein kinase domain (E562K, D564A, Q565E, and R1185C) (3).
Besides the described phenotypes, patients with PHAII due to WNK4 mutations also have hypercalciuria and low bone mineral density (4). The low bone mineral density in PHAII is thought secondary to renal hypercalciuria. In the kidneys, approximately 60% of filtered Ca 2ϩ is passively reabsorbed, mainly through paracellular junctions located in the proximal convoluted tubules (PCT), 20% is absorbed in the thick ascending loops of Henle (TAL) in parallel with Na ϩ reabsorption, and 10 -15% of Ca 2ϩ is actively reabsorbed in the distal nephron (5, 6) . The final rate of Ca 2ϩ excretion is regulated by calbindin, a cytosolic calcium facilitator, and epithelial Ca 2ϩ channels in the late distal convoluted and collecting tubules, the transient receptor potential channel vanilloid subtype 5 (TRPV5) and 6 (TRPV6) (7) . Thus, hypercalciuria may be caused by either increased glomerular Ca 2ϩ filtration and/or reduced Ca 2ϩ tubular reabsorption. Nonetheless, the molecular pathogenesis of hypercalciuria in WNK4-mutation causing PHAII remains unclear. Understanding the mechanisms behind the hypercalciuria in PHAII may provide insight into the accompanying low bone mineral density.
It has been shown through Xenopus oocyte expression that PHAII-mutant WNK4 activate TRPV5-mediated Ca 2ϩ reabsorption less than wild-type WNK in the presence of NCC and was postulated as a mechanism for hypercalciuria in PHAII (8) . However, these in vitro studies may not always directly apply to PHAII patients without further confirmatory in vivo studies. Disease-causing knock-in mouse models more accurately represent human genetic disorders caused by a specific mutation. We have successfully generated Wnk4 D561A/ϩ knock-in mice (corresponding to human D564A) featuring typical phenotypes of human PHAII (9) and hypercalciuria. Using this model, we have uncovered new mechanisms of hypercalciuria in PHAII caused by WNK4 mutations.
Materials and Methods

Preparation of Wnk4
D561A/؉ knock-in mice
The experimental protocols used in the present study were approved by the Institutional Animal Care and Use Committee of the National Defense Medical Center, Taipei, Taiwan. We had created Wnk4 D561A/ϩ knock-in mice (9) 
Blood and urine biochemistry analysis
Blood was collected from the retro-orbital sinus under light ether anesthesia. Mice were housed in metabolic cages for urine collection. Serum and urine biochemistry levels were determined using automated methods (AU 5000 chemistry analyzer; Olympus, Tokyo, Japan). Blood gas data were determined by i-STAT. 
Quantitative real-time PCR (Q-PCR)
For assaying the gene expression of TRPV5 and TRPV6, total kidney RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) and first-strand cDNA synthesized using 2 g of extracted RNA Oligo deoxythymidine primers (Invitrogen) and Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI) following standard RT protocols. The forward (F) and reverse (R) primers used for mouse TRPV5, TRPV6, and ␤-actin gene expression (10) were as follows: TRPV5 (F) 5Ј-GAAACTTCTCAATTGGTGGGTCAG-3Ј, (R) 5Ј-TTTGCCG-GAAGTCACAGTT-3Ј; TRPV6 (F) 5Ј-GTCATGTACTTTGC-CAGAG GA-3Ј, (R) 5Ј-TATAGAAGGCTGAAGCAAATCCCA-3Ј; ␤-actin (F) 5Ј-ACCAC ACCTTCTACAATGAGC-3Ј, (R) 5Ј-GGCACAGTGTGGGTGACC-3Ј.
Q-PCR was undertaken using an Applied Biosystems 7500 RealTime PCR System and the fluorescent dye SYBR Green (Applied Biosystems, Foster City, CA) as a tracer. The ␤-actin gene was used as an internal control. For each target gene, the relative gene expression was performed in triplicate for obtaining a mean cycle threshold (Ct) value and determined as 2 (␤-actin Ct-target gene Ct) , where Ct was the first cycle at which the reporter signal significantly exceeded the baseline signal. Melting curve analysis was carried out after 40-cycles of amplification to validate the size of the PCR products. Amplified PCR products were analyzed using 7500 System SDS software version 1.3.1 (Applied Biosystems). 
Immunoblotting (IB) and immunofluorescent (IF) staining
Semiquantitative IB and IF staining were carried out as per prior reports to assess the relative expression levels and cellular localization of proteins of interest (9) . Proteins (10 g) isolated from whole kidney homogenates without the nuclear fraction (600 ϫ g) for calbindin-D28k (CBP-D28k) or crude membrane fractions (17,000 ϫ g) for apically expressed channels/transporters were firstly loaded onto SDS-PAGE gels and protein samples verified by silver stain and IB of ␤-actin (data not shown) (9) 
Acute and chronic effects of furosemide treatment
Furosemide (15 mg/kg), a NKCC2 inhibitor, was ip administered to the Wnk4 ϩ/ϩ and Wnk4 D561A/ϩ littermates twice per day for three consecutive days. The urine samples in the 8 h after the first dose (acute) and over 24 h on the third day (chronic) were collected for analysis (11) . ; not significant (NS), n ϭ 5] (Fig. 1C) and its cellular localization ( Fig. 2A) ; P Ͻ 0.01, n ϭ 5) were significantly increased in the Wnk4 D561A/ϩ mice (Fig. 1C) . IF revealed enhanced TRPV6 staining in the luminal aspect of distal renal tubules in the Wnk4 D561A/ϩ mice (Fig. 2B) .
Statistical analysis
Expression of NHE3, NKCC2, NCC, and ENaC in
Wnk4 D561A/؉ mice It is well established that in the PCT and TAL, Ca 2ϩ reabsorption runs in parallel to segmental tubular Na ϩ reabsorption (5, 6). We next examined protein expression of a major Na ϩ transporter, NHE3, located in the PCT by semiquantitative IB and IF. There was no significant difference in NHE3 expression (Fig. 3A) or its cellular localization between Wnk4 ϩ/ϩ and Wnk4 D561A/ϩ littermates (Fig. 3B) . In the TAL, however, a significant decrease in NKCC2 expression (72 Ϯ 5% in Wnk4 D561A/ϩ vs. 100 Ϯ 15% in Wnk4 ϩ/ϩ ; P Ͻ 0.01, n ϭ 5) (Fig. 3A) and IF was observed in Wnk4 D561A/ϩ mice (Fig. 3B ). NCC and ENaC(␤) expression were significantly enhanced (Fig.  3) D561A/ϩ mice. These findings support the hypothesis that NKCC2 function is inhibited (Fig. 4) .
Discussion
In congruence with the human disease, Wnk4 D561A/ϩ mice exhibited hypercalciuria in addition to typical PHAII phenotype and entirely confirmed the findings from the previous PHAII transgenic mice model with two additional copies of PHAII (Q562E)-mutant Wnk4 (13) . Serum Cr as an index of glomerular filtration and ionized Ca 2ϩ in Wnk4 D561A/ϩ mice was similar to that in wild-type littermate controls, suggesting that filtered Ca 2ϩ load was not a major contributor to hypercalciuria. Thus, increased urine Ca 2ϩ excretion in Wnk4 D561A/ϩ mice must result from reduced renal tubular Ca 2ϩ reabsorption. Serum levels of PTH and 1,25(OH) 2 D 3 , two important regulators of renal tubular Ca 2ϩ reabsorption (5-7), were also normal and not significantly different between the two groups. These results are consistent with findings in PHAII patients (14) , suggesting that these two hormones are unlikely to contribute to hypercalciuria.
TRPV5 and TRPV6, two epithelial Ca 2ϩ channels primarily responsible for transcellular Ca 2ϩ reabsorption in the distal nephron, are known to colocalize with WNK4. Using the Xenopus oocyte expression system, Jiang et al. (8) showed that PHAII-causing WNK4 mutants significantly enhanced TRPV5-mediated Ca 2ϩ transport by increasing TRPV5 membrane abundance to an extent similar to wild-type WNK4. NCC antagonized the activating effects of wild-type WNK4 on TRPV5 in a dose-dependent manner (8) . In the presence of NCC, PHAII-causing WNK4 mutants exhibited a more impaired ability to enhance TRPV5-mediated Ca 2ϩ uptake compared with wild-type WNK4. Because NCC is overexpressed and activated in PHAII, these in vitro studies suggested that the reduced TRPV5-mediated renal tubular Ca 2ϩ reabsorption by the inhibitory effect of NCC may account for hypercalciuria in PHAII patients with WNK4 mutations (8) . In addition, reduction in TRPV5 and CBP-D28k mRNA and protein expression caused by the metabolic acidosis of PHAII might also be involved in hypercalciuria (15) .
In the case of NCC gain-of-function, PHAII (Q562E) mutant transgenic mice model exhibited the typical phenotype of PHAII and hypercalciuria, which were further enhanced by high NaCl intake and corrected upon crossing with NCC-null mice (13) . These findings indicate that activation of NCC is involved in hypercalciuria and increased Na ϩ delivery to distal tubules further augment urine Ca 2ϩ excretion. However, TRPV5 and TRPV6 expression in the distal renal tubules and upstream Na ϩ and Ca 2ϩ reabsorption were not performed in those animal models. In our Wnk4
D561A/ϩ knock-in mice model, we did not find the reduced TRPV5 but rather increased TRPV6 and CBP-D28k expression in the distal tubules of Wnk4 D561A/ϩ mice. The discrepancy between our and previously reported results remained unclear. Our results suggested that the diminished mRNA or protein abundance of TRPV5 expression in the distal tubules by metabolic acidosis might be counteracted by the causes that regulated tubular Ca 2ϩ reabsorption and delivery to distal tubules. Although TRPV5 expression and cellular localization were not significant difference between wild-type controls and Wnk4 D561A/ϩ mice, we could not exclude the possibility that the phosphorylation and activity of TRPV5 could be enhanced by PHAII-causing WNK4 mutants (9) or other causes without affecting its cellular localization in Wnk4 D561A/ϩ mice (16) . It has recently been shown that patients with PHAII due to WNK4 mutation Q565E had a higher urine Ca 2ϩ to Na ϩ ratio despite the reduced endogenous lithium clearance in PHAII patients (17) . Reduced lithium clearance can be due to either the increased proximal or distal tubular Na ϩ reabsorption (18) . Because increased Na ϩ and Ca 2ϩ reabsorption in proximal renal tubules would lead to hypocalciuria but not hypercalciuria, the enhanced distal tubular Na ϩ reabsorption as reflected by an activated NCC and ENaC activity in Wnk4 D561A/ϩ mice may account for the decreased lithium clearance in PHAII (9) . However, the detailed molecular mechanism of possible aberrant Na ϩ and Ca 2ϩ handling in the upstream nephron of PHAII patients remains unclear.
With their hypertension and low renin levels (9), Wnk4 D561A/ϩ mice must at minimum live in a state of salt-repletion. Their increased NCC and ENaC function in the distal tubules in the setting of similar urine Na ϩ ex- (3, 9, 23) , suggesting that a direct effect of mutant WNK4 on the expression of NKCC2 in TAL were less likely. The importance of volume expansion on urine Ca 2ϩ excretion is also illustrated by the hypercalciuria in mineralocorticoid excess states with ENaC activation and salt-repleted hypertension (24 -26) . Drawing analogy with the hypercalciuria in furosemide-treated mice (11) or patients with NKCC2 inactivating mutations (Bartter's syndrome) (27) , reduced NKCC2 expression in Wnk4 D561A/ϩ mice may diminish lumen-positive potential and in turn decrease Ca 2ϩ reabsorption in the TAL. An increase in TRPV6 and CBPD28k expression was probably a secondary adaptive response to increased Ca 2ϩ load from upstream tubules (11) . Given that PHAII patients with WNK1 mutations also have salt-sensitive hypertension and hyperkalemia without hypercalciuria (28) , one might argue that salt overload may not play a major role in the hypercalciuria of PHAII patients with WNK4 mutations. Due to the widespread expression of Long-WNK1 in renal tubules, some PHAII patients with WNK1 mutations have persistent hypertension even when treated with thiazide diuretics (29) . In fact, NKCC2 and ENaC have been reported to be activated by Long-WNK1 (30, 31) . Thus, Na ϩ channels and transporters other than NCC may be involved in the pathogenesis of hypertension in these patients. Accordingly, Ca 2ϩ reabsorption may be governed by a different mechanism in these patients.
In conclusion, the Wnk4 D561A/ϩ knock-in PHAII mouse model exhibits hypercalciuria with normal glomerular filtration rate, serum ionized Ca 2ϩ , PTH, and 
